SAN FRANCISCO — If last year was a chance for Chinese companies to bet big on biotech and pharma — and also to contend with some disappointment and scandal — this year already appears to be a chance for them to flood the zone.

Chinese companies had a noticeably more visible presence at this week’s J.P. Morgan Healthcare Conference, the industry’s biggest business gathering of the year. U.S. executives and investors have been soaking up the pitch for Chinese biopharma and showing enthusiasm.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • This was a very disappointing fluffy article with only one fact, that one of the many conferences has more attendance. Everyone I know is astounded by the decline in the number of Chinese attendees and with what feels like a decline overall in attendance at Biotech Showcase and JP Morgan. That is an important story because it is a weathervane for things to come. Maybe I and a twenty other people are wrong in our view that this is a very different attendance profile. That is why we need Stat to really analyze this.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy